EP1761191A4 - Evaluation of a treatment to decrease the risk of a progeressive brain disorder or to slow brian aging - Google Patents

Evaluation of a treatment to decrease the risk of a progeressive brain disorder or to slow brian aging

Info

Publication number
EP1761191A4
EP1761191A4 EP05772647A EP05772647A EP1761191A4 EP 1761191 A4 EP1761191 A4 EP 1761191A4 EP 05772647 A EP05772647 A EP 05772647A EP 05772647 A EP05772647 A EP 05772647A EP 1761191 A4 EP1761191 A4 EP 1761191A4
Authority
EP
European Patent Office
Prior art keywords
progeressive
brian
aging
slow
evaluation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05772647A
Other languages
German (de)
French (fr)
Other versions
EP1761191A2 (en
Inventor
Eric M Reiman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Banner Health
Original Assignee
Banner Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Health filed Critical Banner Health
Publication of EP1761191A2 publication Critical patent/EP1761191A2/en
Publication of EP1761191A4 publication Critical patent/EP1761191A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Databases & Information Systems (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
EP05772647A 2004-06-18 2005-06-17 Evaluation of a treatment to decrease the risk of a progeressive brain disorder or to slow brian aging Withdrawn EP1761191A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58076204P 2004-06-18 2004-06-18
PCT/US2005/021557 WO2006009887A2 (en) 2004-06-18 2005-06-17 Evaluation of brain treatment

Publications (2)

Publication Number Publication Date
EP1761191A2 EP1761191A2 (en) 2007-03-14
EP1761191A4 true EP1761191A4 (en) 2008-05-14

Family

ID=35785713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05772647A Withdrawn EP1761191A4 (en) 2004-06-18 2005-06-17 Evaluation of a treatment to decrease the risk of a progeressive brain disorder or to slow brian aging

Country Status (5)

Country Link
US (1) US20050283054A1 (en)
EP (1) EP1761191A4 (en)
CA (1) CA2570539A1 (en)
MX (1) MXPA06014611A (en)
WO (1) WO2006009887A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135519A4 (en) * 1998-12-02 2004-11-24 Univ Pennsylvania Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
US9492114B2 (en) 2004-06-18 2016-11-15 Banner Health Systems, Inc. Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease
US9471978B2 (en) 2004-10-04 2016-10-18 Banner Health Methodologies linking patterns from multi-modality datasets
WO2007114238A1 (en) * 2006-03-30 2007-10-11 National University Corporation Shizuoka University Apparatus for determining brain atrophy, method of determining brain atrophy and program for determining brain atrophy
US20070299360A1 (en) * 2006-06-21 2007-12-27 Lexicor Medical Technology, Llc Systems and Methods for Analyzing and Assessing Dementia and Dementia-Type Disorders
JP5319121B2 (en) 2007-01-30 2013-10-16 株式会社東芝 Medical support system and medical support device
DE102007034956A1 (en) 2007-07-26 2009-02-05 Siemens Ag Method for detecting a neuropathologically altered brain region
US8615479B2 (en) * 2007-12-13 2013-12-24 The Invention Science Fund I, Llc Methods and systems for indicating behavior in a population cohort
US8356004B2 (en) * 2007-12-13 2013-01-15 Searete Llc Methods and systems for comparing media content
US20090156955A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for comparing media content
US20090157660A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems employing a cohort-linked avatar
US20090164302A1 (en) * 2007-12-20 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying a cohort-linked avatar attribute
US20090157751A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying an avatar
US20090164458A1 (en) * 2007-12-20 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems employing a cohort-linked avatar
US8195593B2 (en) * 2007-12-20 2012-06-05 The Invention Science Fund I Methods and systems for indicating behavior in a population cohort
US20090157625A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for identifying an avatar-linked population cohort
US20090157481A1 (en) * 2007-12-13 2009-06-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying a cohort-linked avatar attribute
US9211077B2 (en) * 2007-12-13 2015-12-15 The Invention Science Fund I, Llc Methods and systems for specifying an avatar
US8150796B2 (en) * 2007-12-20 2012-04-03 The Invention Science Fund I Methods and systems for inducing behavior in a population cohort
US9418368B2 (en) * 2007-12-20 2016-08-16 Invention Science Fund I, Llc Methods and systems for determining interest in a cohort-linked avatar
US9775554B2 (en) * 2007-12-31 2017-10-03 Invention Science Fund I, Llc Population cohort-linked avatar
WO2009146388A1 (en) * 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
US9805473B2 (en) * 2008-09-19 2017-10-31 Siemens Healthcare Gmbh Method and system for segmentation of brain structures in 3D magnetic resonance images
WO2010099199A1 (en) * 2009-02-24 2010-09-02 Gibbons Winton G Detection of complexes of tau and amyloid
US9025841B2 (en) * 2009-11-18 2015-05-05 Siemens Aktiengesellschaft Method and system for segmentation of the prostate in 3D magnetic resonance images
DE102011085404A1 (en) * 2011-10-28 2013-05-02 Siemens Aktiengesellschaft Method for measuring structures of the human brain
US9510756B2 (en) * 2012-03-05 2016-12-06 Siemens Healthcare Gmbh Method and system for diagnosis of attention deficit hyperactivity disorder from magnetic resonance images
WO2015060317A1 (en) * 2013-10-22 2015-04-30 長谷川亨 Neurodegenerative disease testing method
EP3074525B1 (en) * 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
US9721316B2 (en) * 2014-01-10 2017-08-01 Bank Of America Corporation Change convergence risk mapping
US10851416B2 (en) 2014-06-24 2020-12-01 Likeminds, Inc. Predictive neurodiagnostic methods
CN105046709B (en) * 2015-07-14 2018-06-29 华南理工大学 A kind of brain age analysis method based on nuclear magnetic resonance image
CN108779159B (en) * 2016-02-04 2022-12-30 瑞泽恩制药公司 Non-human animals with engineered ANGPTL8 genes
WO2018194778A1 (en) * 2017-04-18 2018-10-25 University Of Florida Research Foundation, Inc. Diffusion imaging in parkinson's disease and parkinsonism
US20200166525A1 (en) * 2017-07-25 2020-05-28 Toru Hasegawa Diagnosis-aiding method for determining neurodegenerative disease
BR112020007367A2 (en) * 2017-10-31 2020-09-29 Ge Healthcare Limited medical systems for predicting a disease pathology and for predicting clinical outcome in an individual with uncertain cognitive status, methods for predicting the pathology of a disease and for predicting clinical outcome in an individual with uncertain cognitive status, medical system for identifying individuals who are at risk of developing alzheimer's disease, methods for identifying individuals who are at risk of developing alzheimer's disease, for determining a prognosis for a patient with alzheimer's disease and for treating a patient for alzheimer's disease , use of medical data from one or more individuals with unknown evolution to Alzheimer's disease, and, medical systems for classifying individuals as having mild cognitive impairment or Alzheimer's disease, for classifying individuals as having Alzheimer's disease or some another form of dementia and to identify additional indications for a fa rmaco
CN108830830A (en) * 2018-05-11 2018-11-16 深圳博脑医疗科技有限公司 A kind of quantitative detecting method of brain atrophy, detection device and terminal device
CN109543623B (en) * 2018-11-26 2021-01-29 微医云(杭州)控股有限公司 Fetus development condition prediction device based on nuclear magnetic resonance imaging
EP3893725A1 (en) * 2018-12-10 2021-10-20 Oxford University Innovation Limited Brain imaging
CN111134677B (en) * 2020-02-14 2021-05-04 北京航空航天大学 Magnetic resonance image-based stroke-induced disability prediction method and system
CA3221182A1 (en) * 2021-06-29 2023-01-05 Wen-Yih Tseng Method of evaluating concomitant clinical dementia rating and its future outcome using predicted age difference and program thereof
CN115018836A (en) * 2022-08-08 2022-09-06 四川大学 Automatic dividing and predicting method, system and equipment for epileptic focus
CN117275734A (en) * 2023-11-20 2023-12-22 苏州药明泽康生物科技有限公司 Brain health state assessment method and device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5617861A (en) * 1994-02-16 1997-04-08 Huntington Medical Research Institutes Magnetic resonance spectral analysis of the brain for diagnosis of clinical conditions
US7239908B1 (en) * 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
US6664961B2 (en) * 2000-12-20 2003-12-16 Rutgers, The State University Of Nj Resample and composite engine for real-time volume rendering
US6488221B1 (en) * 2001-05-25 2002-12-03 Maxtec, Inc. Self-aligning, spring-disk waterjet assembly
US7483557B2 (en) * 2003-09-30 2009-01-27 Kabushiki Kaisha Toshiba Medical imaging communication system, method and software
US20050209785A1 (en) * 2004-02-27 2005-09-22 Wells Martin D Systems and methods for disease diagnosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN KEWEI ET AL: "An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease.", NEUROIMAGE MAY 2004, vol. 22, no. 1, May 2004 (2004-05-01), pages 134 - 143, XP002474506, ISSN: 1053-8119 *
REIMAN E M ET AL: "Declining brain activity in cognitively normal apolipoprotein E epsilon4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3334 - 3339, XP003001343, ISSN: 0027-8424 *
REIMAN ERIC M ET AL: "Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 1, 6 January 2004 (2004-01-06), pages 284 - 289, XP002474507, ISSN: 0027-8424 *
SMALL GARY W ET AL: "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 11, 23 May 2000 (2000-05-23), pages 6037 - 6042, XP002474505, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1761191A2 (en) 2007-03-14
MXPA06014611A (en) 2008-03-11
WO2006009887A2 (en) 2006-01-26
CA2570539A1 (en) 2006-01-26
WO2006009887A3 (en) 2006-12-21
US20050283054A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
EP1761191A4 (en) Evaluation of a treatment to decrease the risk of a progeressive brain disorder or to slow brian aging
HUS1900005I1 (en) Improved nanobodies tm for the treatment of aggregation-mediated disorders
EP1786515A4 (en) Treatment of the autonomic nervous system
EP1744751A4 (en) Methods for the treatment of synucleinopathies
PL1890684T3 (en) Treatment of sleep-wake disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
HK1157575A1 (en) Treating neurological disorders
EP1789034A4 (en) Compounds with diphenoyl -structure for the treatment of immune diseases
EP1928452A4 (en) Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
EP1968591A4 (en) Treatment of synucleinopathies
GB0409109D0 (en) Deep brain stimulation
GB0515090D0 (en) Novel epilepsy treatment
EP1732549A4 (en) Methods for the treatment of synucleinopathies
IL189524A0 (en) Imidazole compounds for the treatment of neurological disorders
EP2328584A4 (en) Treatment of neurological disorders using huperzine
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
PL1982178T3 (en) Methods for the treatment of affective disorders
EP2212246A4 (en) Treatment of neurological disorders
IL184316A0 (en) Use of a trpc channel for the treatment of a cardiovascular disease
EP1718329A4 (en) Methods of treating skin disorders
GB0519274D0 (en) The treatment of neurodegenerative diseases
IL178990A0 (en) Methods of treating demyelinating disorders
GB0410966D0 (en) Treatment of neural disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070104

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096277

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080414

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20080404BHEP

Ipc: G01N 33/50 20060101ALI20080404BHEP

Ipc: A61B 5/00 20060101ALI20080404BHEP

Ipc: A61B 19/00 20060101AFI20070207BHEP

17Q First examination report despatched

Effective date: 20080908

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090319

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1096277

Country of ref document: HK